Compare KraneShares Electric Vehicles and Future Mobility (KARS) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KraneShares Electric Vehicles and Future Mobility vs Viatris Inc — how do they compare? KraneShares Electric Vehicles and Future Mobility trades at $30.53, while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: Viatris Inc pays a 2.95% dividend while KraneShares Electric Vehicles and Future Mobility pays none, and Viatris Inc is trading nearer its 52-week high, KraneShares Electric Vehicles and Future Mobility nearer its low. Which is the better fit depends on your goals.
| KARS | VTRS | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $38.01 | $17.86 |
52-Week Low | $25.59 | $9.49 |
Market Cap | — | $18.69B |
Enterprise Value | — | $30.81B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KARS trades at $30.86, up 2.51% today, with a bullish technical signal but bearish moving averages. Recent news highlights global EV sales growth, particularly in Europe and China, though U.S. adoption lags. The stock shows strong momentum with RSI_6 at 80.23 indicating overbought conditions, while support and resistance cluster around $30-$31.
The outlook for KARS is mixed; positive EV industry trends support growth, but high RSI suggests near-term pullback risk. Investment opportunity lies in global EV expansion, while risks include U.S. market hesitation and competitive pressures from Chinese automakers.
Viatris (VTRS) trades at $16.43, up 0.86% with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $0.69, exceeding expectations, with revenues rising 5% year-over-year. However, fundamental challenges persist with negative net income margin (-2.79%) and elevated P/E ratio (236.2). Recent developments include FDA approval for Gwyn Lo contraceptive patch and strategic divestitures to sharpen focus.
While Viatris shows operational improvements with consistent cash flow generation, the stock faces headwinds from profitability challenges and high valuation multiples. The mixed analyst sentiment (30.77% buy rating) reflects uncertainty about the company's turnaround trajectory. Key risks include ongoing margin pressure and competitive threats in the generic pharmaceutical space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About KraneShares Electric Vehicles and Future Mobility
KARS invests in the global electric vehicle ecosystem and future mobility. It tracks the Bloomberg Electric Vehicles Index, providing exposure to EV manufacturers, battery technology, and lithium miners like Tesla, BYD, and Albemarle.
Read more on KARS →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
